

**Emergent Technologies, Inc. Establishes Technology Evaluation and  
Research Collaboration Agreement with Merck  
to identify siRNA Delivery Technologies**

**AUSTIN, TX – June 4, 2010** – Emergent Technologies, Inc. (ETI), a leading life sciences technology investment and management firm, announced today that they have signed a technology evaluation and research collaboration agreement with Merck, (through a subsidiary) in the field of small interfering RNAs (siRNAs). ETI will augment Merck's siRNA initiatives by identifying and refining technologies for the delivery of siRNA. Additional details of the agreement were not disclosed.

ETI CEO Thomas A. Harlan said, "We are very pleased to be collaborating with Merck, a global leader in pharmaceutical research. With ETI's broad reach into commercial organizations and academic institutions, we have demonstrated our ability to convert scientific breakthroughs into technologies that fit commercial specifications and provide significant competitive advantages. Our unique capabilities in bridging the gap between discovery and product are valuable resources to identify, evaluate and refine siRNA technologies for commercial suitability."

Added ETI Vice President Gregory Pogue, Ph.D., "We view siRNA as a paradigm-shifting technology with the potential to fundamentally change the treatment of many human diseases. This technology can advance the science of human healthcare and lead to the development of new therapeutics. It is one of the most rapidly advancing fields in drug development today."

**RNAi/siRNA**

RNA interference (RNAi) is a system within living cells that helps to control which genes are active and how active they are. Specifically designed short interfering RNA (siRNA) molecules are central to RNAi. In 2006 the Nobel Prize for Physiology or Medicine was awarded for RNAi work on how genes are controlled within living cells.

**About Emergent Technologies, Inc.**

Emergent Technologies, Inc. is a life sciences technology investment and management company which provides early stage funding and development for scientific discoveries originating at universities and research institutions. ETI creates value by transforming scientific breakthroughs into technology platforms with multiple applications. ETI's unique innovation process enables ETI to select promising scientific discoveries for development, maximize the value of

--more--

**Page 2 of 2**

**Emergent Technologies, Inc. Establishes Technology Evaluation and Research Collaboration Agreement with Merck to identify siRNA Delivery Technologies**

Intellectual property and manage both cost and risk associated with the commercial development of early stage technologies. ETI is dedicated to turning research into revenue and, in the process, introducing compelling solutions to meet important market needs. For more information, visit the company website [www.etibio.com](http://www.etibio.com).

###

**Media Contact:**

Sandra Oak  
Nsight Public Relations  
Phone: 321-591-1508  
E-mail: [soak@nsightpr.com](mailto:soak@nsightpr.com)